Targeting the eicosanoid pathway in hepatocellular carcinoma.

Razdan, Anshuli; Main, Nathan M; Chiu, Vincent; Shackel, Nicholas A; de Souza, Paul; Bryant, Katherine; Scott, Kieran F

Razdan, Anshuli; Main, Nathan M; Chiu, Vincent; Shackel, Nicholas A; de Souza, Paul; Bryant, Katherine; Scott, Kieran F.

Afiliação

Razdan A; School of Medicine, Western Sydney University Sydney, NSW, Australia.
Main NM; Department of Medical Oncology, Ingham Institute for Applied Medical Research Sydney, NSW, Australia.
Chiu V; Gastroenterology and Liver Laboratory, Ingham Institute for Applied Medical Research Sydney, NSW, Australia.
Shackel NA; Gastroenterology and Liver Laboratory, Ingham Institute for Applied Medical Research Sydney, NSW, Australia.
de Souza P; Gastroenterology and Liver Laboratory, Ingham Institute for Applied Medical Research Sydney, NSW, Australia.
Bryant K; School of Medicine, Western Sydney University Sydney, NSW, Australia.
Scott KF; Department of Medical Oncology, Ingham Institute for Applied Medical Research Sydney, NSW, Australia.

Am J Cancer Res ; 11(6): 2456-2476, 2021.

Article em En | MEDLINE | ID: mdl-34249410

Palavras-chave

Hepatocellular carcinoma; NAFLD; cirrhosis; cyclooxygenase; cytochrome P450; eicosanoids; fibrosis; inflammation; lipoxygenase; phospholipase A2

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Am J Cancer Res Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Austrália

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google